Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.58 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947605 | 0.91 | TBXAS1 (0.67) | POLBTBXAS1CYP19A1NPC1RAB9A | |
| SCHEMBL11257445 | 0.85 | TBXAS1 (0.58) | TBXAS1EGLN3CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6950296 | 0.85 | TBXAS1 (0.58) | TBXAS1EGLN3CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL7241260 | 0.84 | CYP19A1 (0.72) | POLBCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3255191 | 0.84 | TBXAS1 (0.78) | TBXAS1EGLN3CYP19A1 | |
| SCHEMBL6948630 | 0.84 | NOS1 (0.56) | POLBTBXAS1EGLN3CYP19A1NPC1 | |
| Hydrochloric Acid SCHEMBL408241 | 0.84 | TBXAS1 (0.57) | TBXAS1EGLN3CYP19A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL411527 | 0.83 | TBXAS1 (0.76) | TBXAS1EGLN3CYP19A1 | |
| Hydrochloric Acid SCHEMBL9996091 | 0.83 | CYP19A1 (0.70) | POLBCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL11373689 | 0.82 | TBXAS1 (0.67) | TBXAS1EGLN3CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| EP-0709378-B1 | Aminoalkyloximes, a process for their preparation, their use as medicaments and intermediate compounds | AVENTIS PHARMA INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| US-5770740-A | TREATING DEPRESSION AND OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5696142-A | TREATING DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5686447-A | ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5686483-A | TREATING DEPRESSION AND OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5686446-A | ANTIDEPRESSANTS, OBSESSIVE COMPULSIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5684021-A | Aminoalkyloximes for treating depression and affective disorders | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5665756-A | Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders | HOECHST MARION ROUSSEL, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5648367-A | ANTIDEPRESANTS, OBSESSIVE-COMPULSIVE DISORDER | HOECHST MARION ROUSSEL, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| EP-0709378-A2 | Aminoalkyloximes, a process for their preparation, their use as medicaments and intermediate compounds | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | POLB 3866/4885TBXAS1 1494/4885EGLN3 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.